8-K
Esperion Therapeutics, Inc. (ESPR)
8-K
2025-10-07
For: 2025-10-07
View Original
Added on
April 09, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) ofthe Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 7, 2025
EsperionTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35986 | 26-1870780 |
|---|---|---|
| (State<br> or other jurisdiction of<br><br> incorporation) | (Commission<br>File Number) | (I.R.S.<br> Employer<br> Identification No.) |
| 3891 Ranchero Drive, Suite 150 Ann Arbor, MI | ||
| --- | ||
| (Address<br>of principal executive offices) |
48108
(Zip Code)
Registrant’s telephone number, including area code:
(734
) 887-3903
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | ESPR | NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On October 7, 2025, Esperion Therapeutics, Inc. (the “Company”) posted an updated corporate presentation to its website at https://www.esperion.com/investors-media. A copy of the updated corporate presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company’s website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Corporate<br> Presentation dated October 2025. |
| 104 | The cover<br> page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 7, 2025 | Esperion Therapeutics, Inc. | |
|---|---|---|
| By: | /s/<br> Sheldon L. Koenig | |
| Sheldon<br> L. Koenig | ||
| President<br> and Chief Executive Officer |
Exhibit 99.1
| Esperion Corporate Presentation<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>October 2025 |
|---|
| 2 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>Forward-looking Statements & Disclosures<br>This pre s e ntation c ontains forward-looking s tate me nts of Es pe rion The rape utic s , Inc . (“Es pe rion,” “we ,” or “our”) that are made purs uant to the s afe harbor provis ions of the fe de ral s e c uritie s laws ,<br>inc luding s tate me nts re garding marke ting s trate gy and c omme rc ialization plans , c urre nt and planne d ope rational e xpe ns e s , e xpe cte d profitability, future ope rations , c omme rc ial produc ts , c linic al<br>de ve lopme nt, plans for pote ntial future produc t c andidate s , financ ial c ondition and outlook, inc luding e xpe c te d c as h runway and profitability, and othe r s tate me nts c ontaining the words “antic ipate ,”<br> “be lie ve ,” “e s timate ,” “e xpe c t,” “inte nd,” “may,” “plan,” “pre dic t,” “proje c t,” “s ugge s t,” “targe t,” “pote ntial,” “will,” “would,” “c ould,” “s hould,” “c ontinue ,” and s imilar e xpre s s ions . Any e xpre s s or implie d<br>s tate me nts c ontaine d in this pre s e ntation that are not s tate me nts of his toric al fac t may be de e me d to be forward-looking s tate me nts. Forward-looking s tate me nts involve ris ks and unc e rtaintie s that c ould<br>c aus e Es pe rion’s ac tual re s ults to diffe r s ignific antly from thos e proje c te d, inc luding, without limitation, the ne t s ale s , profitability, and growth of Es pe rion’s c omme rc ial produc ts , c linic al ac tivitie s and<br>re s ults , s upply c hain, c omme rc ial de ve lopme nt and launc h plans , the outc ome s and antic ipate d be ne fits of le gal proc e e dings and s e ttle me nts , and the ris ks de taile d in Es pe rion’s filings with the Se c uritie s<br>and Exc hange Commis s ion (the “SEC”), inc luding in Es pe rion’s mos t re c e nt Annual Re port on Form 10-K and in any s ubs e que nt filings with the SEC. Any forward-looking s tate me nts c ontaine d in this<br>pre s e ntation s pe ak only as of the date he re of, and Es pe rion dis c laims any obligation or unde rtaking to update or re vis e any forward-looking s tate me nts c ontaine d in this pre s e ntation, othe r than to the<br>e xte nt re quire d by law. No re pre s e ntations or warrantie s (e xpre s s e d or implie d) are made about the ac c urac y of any s uc h forward-looking s tate me nts .<br>Ce rtain information c ontaine d in this pre s e ntation re late s to or is bas e d on s tudie s , public ations , s urve ys and othe r data obtaine d from third-party s ourc e s and Es pe rion’s own inte rnal e s timate s and<br>re s e arc h. While Es pe rion be lie ve s the s e third-party s tudie s , public ations , s urve ys and othe r data to be re liable as of the date of this pre s e ntation, Es pe rion has not inde pe nde ntly ve rifie d, and make no<br>re pre s e ntation as to the ade quac y, fairne s s , ac c urac y or c omple te ne s s of, any information obtaine d from third-party s ourc e s . In addition, no inde pe nde nt s ourc e has e valuate d the re as onable ne s s or<br>ac c urac y of Es pe rion’s inte rnal e s timate s or re s e arc h and no re lianc e s hould be made on any information or s tate me nts made in this pre s e ntation re lating to or bas e d on s uc h inte rnal e s timate s and<br>re s e arc h. Finally, Es pe rion has not c onduc te d any he ad-to-he ad s tudie s c omparing its produc t c andidate s to any third party drug produc ts or c andidate s , whe the r inve s tigate d or approve d. Information<br>re garding othe r drug produc ts in this pre s e ntation is me ant to provide c onte xt for illus trative purpos e s only. Be c aus e the re are no head-to-he ad s tudie s , no c onc lus ions s hould be made bas e d on c ros s<br>s tudy c omparis ons . Re c ipie nts are c autione d not to plac e undue re lianc e on the s e forward looking s tate me nts , whic h s pe ak only as of the date s uc h s tate me nts are made and s hould not be c ons true d as<br>statements of fact. |
| --- |
| Clear Strategic Plan for Success<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>3<br>Expand Bempedoic Acid<br>Franchise Globally<br> • Key ANDA settlements provide<br>the potential to secure additional<br>years of exclusivity, extending<br>blockbuster revenue potential<br> • Settlement agreements for April<br>19, 2040 reached with:<br> • Dr. Reddy’s Laboratories<br> • Micro Labs USA, Inc.<br> • Hetero USA Inc.<br> • Accord Healthcare Inc.<br> • Deploying a balanced in-person<br>and digital engagement strategy<br>that has accelerated physician<br>adoption – and serve as a driver<br>for growth<br> • Leveraging global partnerships<br>to support meaningful revenue<br>growth and expand market<br>awareness worldwide<br>Transition to Cash Generating<br>Pharmaceutical Company<br>Pipeline Advancement and<br>Portfolio Expansion<br> • Advancing our internally<br>developed and wholly owned<br>development pipeline<br> • Advancing development of triple<br>combination products in the U.S.<br>to unlock additional growth<br>opportunities<br> • Potential acquisition or in-licensing of cardiometabolic<br>products that are synergistic with<br>our commercial call point<br> • Operating income from ongoing<br>business in the second quarter<br>2025 supports expectations for<br>sustainable profitability<br> • Revenue growth from expanding<br>product adoption and geographic<br>reach supporting profitability<br>objectives<br>ANDA – Abbreviated New Drug Application |
| --- |
| Strategic Priorities<br>4 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>Expand Bempedoic Acid<br>Franchise Globally<br> • Invest in targeted marketing<br>initiatives to accelerate physician<br>adoption and broaden patient<br>access<br> • Expand reach of sales team<br>through targeted territory additions<br>and enhanced patient activation<br>programs<br> • Increase consumer awareness<br>and drive demand through<br>consumer-activated educational<br>initiatives<br> • Lay the foundation for sustained<br>growth, positioning the franchise<br>for multiple years of blockbuster<br>status<br>Transition to Cash Generating<br>Pharmaceutical Company<br>Pipeline Advancement and<br>Portfolio Expansion<br> • Drive clinical development of PSC<br>program<br> • Accelerate kidney program<br>development to expand potential<br>therapeutic impact<br> • Advance label-expanding trials<br>for the triple combination therapy<br> • Support potential acquisition or<br>in-licensing of complementary<br>assets to drive long-term growth<br> • Cementing the path to<br>profitability<br> • Enhancing long-term cash<br>generation potential through a<br>potentially lengthened exclusivity<br>period |
| --- |
| Financial Highlights<br>5 © 2025 Esperion. All Rights Reserved – Do not copy or distribute.<br>0<br>10<br>20<br>30<br>40<br>50<br>60<br>70<br>80<br>90<br>Q1 2025 Q2 2025<br>65.0<br>Total Net Revenue<br>(in $MM)<br>+27%<br>0<br>5<br>10<br>15<br>20<br>25<br>30<br>35<br>40<br>45<br>Q1 2025 Q2 2025<br>35.0<br>U.S. Product Revenue<br>(in $MM)<br>+15%<br>0<br>5<br>10<br>15<br>20<br>25<br>30<br>35<br>40<br>Q1 2025 Q2 2025<br>30.1<br>Collaboration Revenue<br>(in $MM)<br>+40%<br>82.4 40.3<br>42.1 Cash & Cash Equivalents<br>$86.1M<br>as of June 30, 2025<br>Q2 2025 First Quarter of<br>Operating Income from<br>Ongoing Business in<br>Company’s History |
| --- |
| -<br> 20,000<br> 40,000<br> 60,000<br> 80,000<br> 100,000<br> 120,000<br> 140,000<br> 160,000<br> 180,000<br> 200,000<br> 220,000<br> 240,000<br>Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25<br>Strong Prescription Trend and Increasing<br>Physician Adoption Continue to Drive Durable<br>Revenue Growth<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>6<br>Quarterly Franchise Retail Prescription Equivalents<br>(RPE) Trend<br>Weekly Franchise RPE Trend1<br>1. Through June 30, 2025.<br>+10%<br>RPE<br>Growth<br> -<br> 2,000<br> 4,000<br> 6,000<br> 8,000<br> 10,000<br> 12,000<br> 14,000<br> 16,000<br> 18,000<br> 20,000<br>1/6/23 1/6/24 1/6/25 |
| --- |
| Driving U.S. and Global Growth and<br>Reaching Profitability |
| --- |
| 1. Shen M, et al. J Am Heart Assoc, 2022;11:3026075. 2. Metser G. et al. Am J Cardiol. 2021;161:36-41 . 3.Allen JM, et al. Circulation. 2019;140:A12904. 4. Yang Y, et al. Circulation.<br>2021;144:A10434. 5. Wong ND, et al. J Clin Lipid.2016;10:1109-1118. 6. Cheeley MK, et al. J Clin Lipidol. 2022 Jul-Aug;16(4):361-375. 7. Ahmad FB, Anderson RN. JAMA. 2021;325(18):1829-<br>1830. 8. Tsao C, et al. Circulation. 2023;147:e93-e621. 9. Int J Environ Res Public Health. 2022 Jul 6;19(14):8272. doi: 10.3390/ijerph19148272.10. Gu J, et al. Am J Prev Cardiol. 2022 Mar<br>20;10:100336.<br>Despite Statins, an Ongoing Medical Need for<br>Oral Therapies Remains<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>8<br>~44% ~53%<br>of US adults with, or at risk<br>for, CVD are not at<br>recommended LDL-C<br>levels3,4,5<br>High levels of LDL-C are the main risk<br>factor for CVD9<br>CVD remains a leading health risk in<br>US men and women7,8<br>of US adults are at high-risk<br>or have experienced a CV<br>event1,2<br>Statins alone are not enough to<br>optimize LDL-C and prevent CVD10<br>~30%<br>of US adults are unable to<br>take recommended statin<br>therapy 6<br>Marketing & Sales Strategic Focus Area:<br>Our near-term priority population<br>LDL-C: Low-Density Lipoprotein Cholesterol CVD: Cardiovascular Disease |
| --- |
| 1. Allen JM, et al. Circulation. 2019;140:A12904. 2. Shen M, Nargesi AA, et al. J Am Heart Assoc. 2022;11:e026075. 3. Yang Y, et al. Circulation. 2021;144:A10434. 4. Wong ND, et al. J Clin<br>Lipidology. 2016;10:1109-1118. 5. Bytyci I, et al. Eur Heart J. 2022;00:1-16. 6. Total U.S. Resident Population by Age, Sex, and Series: April 1, 2020 [table]; US Census Bureau: 2020. 7.<br>Symphony Data as of Dec 31, 2024.<br>Significant and Growing U.S. Market Opportunity<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>9<br>Over 70 million at-risk patients are<br>undertreated or not treated<br>Rising need drives double-digit growth in<br>the non-statin market<br>Branded non-statin therapies are leading<br>growth in the non-statin market<br>Non-Statin Prescription Volume7<br>13.0M<br>14.9M<br>17.7M<br>21.1M<br>10<br>12<br>14<br>16<br>18<br>20<br>22<br>2021 2022 2023 2024<br>TRx, Millions<br>Branded Non-Statin Prescription Volume7<br>2.7M<br>3.2M<br>4.0M<br>5.2M<br>0<br>1<br>2<br>3<br>4<br>5<br>6<br>2021 2022 2023 2024<br>TRx, Millions<br>~10M<br>Under-Treated High-Risk<br>Primary Prevention &<br>ASCVD Patients2,3,4,5<br>Under-Treated ASCVD<br>Patients1<br>+ ~20M<br>+ ~40M<br>Untreated High-Risk Primary<br>Prevention & ASCVD<br>Patients 1,2,5,6<br>+14.6%<br>+18.6%<br>+18.0%<br>+19.7%<br>+26.7%<br>+29.5% |
| --- |
| Bempedoic Acid Received 1a Recommendation in Updated<br>ESC/EAS Guidelines for Management of Dyslipidaemias<br>10 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br> • Bempedoic acid was the only new non-statin included with<br>LDL-C and CV risk reduction data.<br> • First time a guideline has given a Level IA to recommend<br>combination therapy based on magnitude of LDL-C reduction<br>needed.<br>Strike early, strike strong<br>Recommendations Class Level<br>Non-statin therapies with proven cardiovascular<br>benefit (including bempedoic acid), taken alone or in<br>combination, are recommended for patients who are<br>unable to take statin therapy to lower LDL-C levels<br>and reduce the risk of CV events. The choice should<br>be based on the magnitude of additional LDL-C<br>lowering needed.<br>I A<br>Bempedoic acid is recommended in patients who are<br>unable to take statin therapy to achieve the LDL-C<br>goal.<br>I B<br>The addition of bempedoic acid to the maximally<br>tolerated dose of statin with or without ezetimibe<br>should be considered in patients at high or very high<br>risk in order to achieve the LDL-C goal.<br>IIa C<br>European Guidelines Expected to Inform Upcoming U.S. Cholesterol Treatment Guidelines |
| --- |
| Filling the Treatment Gap: Our Breakthrough in<br>LDL-C Management<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>11<br>Ezetimibe<br>STATINS NON-STATIN THERAPIES<br> • Mostly generic<br> • First-line, widely<br>used<br> • Combinable for<br>incremental LDL-lowering<br> • 25-55% drops in<br>LDL-C<br>CV Risk Reduction Indication 1<br>LDL-C Lowering 2<br>Primary Prevention<br>Secondary Prevention<br>Use Without a Statin<br><br><br><br><br><br><br><br><br><br>PCSK9i<br>mAbs<br>PCSK9i<br>siRNA<br><br><br><br><br><br>Observed LDL-C Reduction 19% 17-18% 38%<br>Administration<br><br>48-71% 48-52%<br>1. Variations within the specific wording of each product indication.<br>No head-to-head studies have been conducted; cross-study data reflect different study designs, populations, and other features. |
| --- |
| The Next Step in Cardiovascular Risk Reduction<br>12<br>CV Risk Reduction<br>27%<br>Nonfatal MI<br>Coronary<br>Revascularization<br>19%<br>CLEAR Outcomes<br><br>Primary Prevention*<br>32%<br>MACE-4<br>(nonfatal MI, coronary revascularization,<br>nonfatal stroke, or CV death)<br>LDL-C Reduction<br>38%<br>Not activated in<br>skeletal muscle<br>Does not raise<br>glucose<br>Reduces hsCRP<br>Use with or without a<br>statin<br>HR, 0.73 (95% CI: 0.62-0.87)<br>HR, 0.81 (95% CI: 0.72-0.92) HR, 0.68 (95% CI: 0.53-0.87)<br>The primary endpoint was percent<br>change from baseline to Week 12 in<br>LDL-C. Results shown are based on a<br>mean 38% placebo-corrected LDL-C<br>reduction<br>(-36% NEXLIZET vs +2% placebo)<br>RRR<br>30% of patients<br>enrolled have not<br>had their first event<br>but are at high risk<br>RRR RRR<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>* - As pre-specified exploratory analysis |
| --- |
| Strengthening Access and Driving Growth<br>13 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br> • 10% increase in total retail prescription equivalents vs. Q1<br>2025<br> • Now over 28,000 total HCPs<br> • 23% of prescriptions written by physicians with only digital<br>touchpoints<br> • 38% of new writer prescriptions were driven by digital only<br>touchpoints<br> • Approval rates of more than 80% following education of<br>1,100+ target prescribers by our expanded U.S. fields<br>reimbursement team<br>Expanded payer coverage and<br>reduced prior authorization<br>requirements<br>Q2 2025 Resulted in:<br>Enhanced reimbursement<br>support resources for patients<br>and providers<br>Balanced direct and digital<br>marketing approach |
| --- |
| Strategic Partnerships Driving Billion $ Global Opportunity<br> © 2025 Esperion Therapeutics, Inc. All rights reserved. 14<br>Partner Daiichi Sankyo Europe<br>Asia & South America<br>Daiichi Sankyo Co., Ltd. Otsuka Pharmaceutical Co.,<br>Ltd.<br>Agreement Terms<br>Neopharm Israel HLS Therapeutics<br>Tiered royalties and<br>additional sales milestones<br> • Received approval<br>in Q3 2025<br> • National Health<br>Insurance pricing<br>approval in Q4<br>2025<br>Europe<br>Maximizing Global Reach Across Key Regions<br>Japan<br>Tiered royalties, regulatory,<br>pricing and additional sales<br>milestones<br>Tiered royalties and<br>additional sales milestones<br> • Launched in many key<br>markets including<br>Germany, UK, Austria,<br>Belgium, Switzerland,<br>Italy, Spain, Netherlands,<br>Slovakia and Czech<br>Republic to date<br> • Expanded label approved<br>in EU and UK in May/June<br> ’24<br>Highlights<br> • Received regulatory<br>approval to market<br>product (mono & dual) and<br>launched:<br> • Hong Kong in 2023<br> • Thailand and Macau in<br>2024<br> • Received regulatory<br>approval to market<br>product (mono)<br> • Myanmar and Taiwan<br>in 2024<br>Israel Canada<br>Tiered royalties<br>and additional<br>milestones<br> • Filed NDA for<br>marketing<br>approval in Q1<br>2025; approval<br>anticipated in<br>the first half of<br>2026<br> • Expect<br>market<br>approval in<br>Q4 2025<br>Upfront Payment,<br>Milestones and<br>Tiered Royalties<br>40<br>Approved in<br>countries<br>globally<br>A p p r o v a l a n d l a u n c h i n a d d i t i o n a l t e r r i t o r i e s a n t i c i p a t e d i n Q 4 2 0 2 5 a n d b e y o n d<br>Australia &<br>New Zealand<br>CSL Seqirus<br>Upfront and near-term milestone<br>payments<br> • Filed marketing<br>application in<br>Australia in July<br>2025<br> • Expect market<br>approval in Q4<br>2026 |
| --- |
| Pipeline Advancement |
| --- |
| Renal Diseases To Be Announced<br>Primary Sclerosing Cholangitis<br>(PSC) IND: 2026<br>PRODUCT/PROGRAM EXPLORATORY LEAD ID<br>LEAD<br>OPTIMIZATION<br>PRECLINICAL<br>DEVELOPMENT<br>CLINICAL<br>DEVELOPMENT<br>APPROVED /<br>COMMERCIAL MILESTONES<br>Proven Science, Innovative Pipeline<br>16 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>I n n o v a t i v e P o r t f o l i o & P i p e l i n e<br>NEXLETOL®<br> bempedoic acid<br>Approved 2020<br>Expanded label 2024<br>NEXLIZET®<br> bempedoic acid and ezetimibe<br>Approved 2020<br>Expanded label 2024<br>Triple Combination A<br> bempedoic acid, ezetimibe, and atorvastatin NDA: 2027<br>Triple Combination B<br> bempedoic acid, ezetimibe, and rosuvastatin NDA: 2027<br>Cardiovascular Disease (LDL-C lowering / CV Risk reduction)<br>LDL-C: low-density lipoprotein cholesterol; CV: cardiovascular; NDA: New Drug Application; IND: Investigational New Drug<br>Liver Diseases |
| --- |
| Oral Triple Combination<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>17<br>1. Product in development, not approved, LDL-C data based on literature evaluating co administered products (Rubino et.al Atherosclerosis 320 (2021) 122-128, Mahajan et.al. J. Clin. Lipidology<br>(2004), Vol 18 (5) e867-872; 2. USPI for Zetia (November 2024), monotherapy and on statin; 3. New Amsterdam Pharma corporate presentation (Jan 2025); 4. USPI for Repatha (Nov 2024),<br>Praluent (March 2024) and Leqvio (July 2024)<br>No head-to-head studies have been conducted; cross-study data reflect different study designs, populations, and other features.<br>Approval Status<br>LDL-C reduction<br>Administration<br>Dosing<br>In development<br>~ 60% - 70%<br>Once daily<br>Triple<br>Combo1<br>Approved/Generic<br>19%<br>Once daily<br>In development<br>33%<br>Once daily<br>3 approved products<br>~ 48% - 71%<br>Bi-weekly to 6 months<br>Ezetimibe2 Obicetrapib3 PCSK9i4<br>Oral CETP inhibitor not approved with unknown safety profile. No<br>proven CV RR data. PCSK9i products are injectable. |
| --- |
| PSC: High Unmet Medical Need Driving Significant<br>Market Opportunity<br>18 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>2024<br>Diagnosed Prevalence of PSC<br>US EU<br>1. Bakhshi Z, et al. J Gastroenterol. 2020 May;55(5):523-532.; 2. Nguyen A, et al. Front Gastroenterol (Lausanne).<br>2022;1:1076788.; 3. Liang H, et al. Medicine (Baltimore). 2017;96(24):e7116.; 4. Boonstra K, et al. Hepatology.<br>2013;58(6):2045-55.; 5. Krampe, J, et al. Poster presented at: ISPOR 2024; Nov 2, 2024; Barcelona, Spain<br>Annual Market Opportunity Estimate<br> • No approved therapies with proven efficacy to<br>cure or halt PSC progression<br> • High healthcare burden from hospitalization,<br>transplants, and long-term management costs<br> • Death or liver transplantation expected within 1-<br>2 decades after diagnosis<br> • Potential Orphan Drug Designation & Fast Track<br>Approval<br> • Discovery program is internally developed and<br>wholly-owned globally<br>PSC: A Rare and Progressive<br>Liver Disease<br>30K3-5<br> >$1B<br>46K1-2<br>~76K<br>PSC: primary sclerosing cholangitis |
| --- |
| Development Timeline<br>2025 2026 Early 2030’s<br>Pre-IND Interactions<br>with FDA<br>Pre-Clinical<br>IND-Enabling Studies<br>IND Filing<br>Phase 1 Clinical<br>Studies<br>Commercialization / Market Launch<br>FDA: Food and Drug Administration<br>IND Enabling Clinical Development Registration/Launch<br>Candidate<br>Nomination<br>Discovery<br>19 © 2025 Esperion Therapeutics, Inc. All rights reserved. |
| --- |
| Experienced Leaders, Breakthrough Results<br>20 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>Sheldon Koenig<br>PRESIDENT AND CHIEF<br>EXECUTIVE OFFICER<br>Glenn Brame<br>CHIEF TECHNICAL<br>OPERATIONS OFFICER<br>Betty Jean Swartz<br>CHIEF BUSINESS OFFICER<br>Ben Looker, Esq.<br>GENERAL COUNSEL<br>Ben Halladay<br>CHIEF FINANCIAL OFFICER<br>Stephen Pinkosky<br>VP, EARLY & PRE-CLINICAL<br>DRUG DISCOVERY<br>LeAnne Bloedon<br>VP, CLINICAL<br>DEVELOPMENT<br>Heather Persh<br>VP, HUMAN RESOURCES<br>Satish Nachaegari<br>VP, GLOBAL REGULATORY<br>AFFAIRS |
| --- |
| Appendix |
| --- |
| Significantly Differentiated from Potential<br>Competitors<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>22<br>Commercially Available<br>Bempedoic Acid1<br> (alone and in combination with ezetimibe)<br>CV Risk Reduction<br>MACE-4: -13%<br>MACE-3: -15%<br>CV Risk Reduction in Primary Prevention MACE-4: -32%<br>MACE-3: -39%<br>FDA Approved for CV Risk Reduction<br>Safety & Tolerability<br>Demonstrated safety in 9,000+ patients across<br>Phase 3 clinical trials<br> Primary & Secondary Prevention<br>Obicetrapib: Not available (Q4 2026*)<br>Torceptrapib: +25%3<br><br>Dalcetrapib & Evacetrapib: No change4-5<br>Anacetrapib: -9%6<br><br>CETPi<br>Long-term safety of obicetrapib not established2<br>Safety concerns halted dev. on 4 previous<br>CETPis due to ↑ death & CV risk, clinical futility<br>and fat tissue accumulation3-6<br>Concern for macular degeneration from genetic<br>studies7<br><br>Not planned<br>Bempedoic acid: -17-20%<br>Bempedoic acid + ezetimibe: -38% LDL-C Lowering<br>Obicetrapib: -33-35%2<br>Torceptrapib: -25%3<br>Dalcetrapib: No difference4<br>Evacetrapib: -37%5<br>Anacetrapib: -40%6<br>CETPi: cholesterol ester transfer protein; MACE-4: CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization; MACE-3: CV death, nonfatal myocardial infarction, or nonfatal stroke 1. Nexletol (bempedoic acid) Tablets [Package Insert]; Nexlizet<br>(bempedoic acid and ezetimibe) [Package Insert] Ann Arbor, MI: Esperion Therapeutics, Inc.; 2. New Amsterdam Pharma Conference Call Presentation December 10, 2024. 3. N Engl J Med. 2007;357:2109–22; 4. N Engl J Med. 2012;367:2089–99; 5. N Engl J Med.<br>2017;376:1933–1942; 6. N Engl J Med. 2017;377:1217–1227.; 7. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:7401–6<br>Esperion has not conducted any head-to-head studies comparing its product candidates to any third party drug products or candidates, whether investigated or approved. Information regarding other drug products in this presentation is meant to provide context for<br>illustrative purposes only. Because there are no head-to-head studies, no conclusions should be made based on cross study comparisons. *estimated trial primary completion date |
| --- |
| Significantly Differentiated from Potential<br>Competitors cont.<br> © 2025 Esperion Therapeutics, Inc. All rights reserved.<br>23<br>Commercially Available<br>Bempedoic Acid1<br> (alone and in combination with ezetimibe)<br>CV Risk Reduction MACE-4: -13%<br>MACE-3: -15%<br>Not available (Q3 2029*)<br><br>PCSK9i<br>[enlicitide decanoate (MK-0616)]<br>CV Risk Reduction in Primary Prevention MACE-4: -32%<br>MACE-3: -39%<br>FDA Approved for CV Risk Reduction<br>Safety & Tolerability Demonstrated safety in 9,000+ patients across<br>Phase 3 clinical trials<br>Primary & Secondary Prevention<br><br>Administration Oral • Oral (requires fasting 8 hours prior and 30<br>minutes after)<br> • 50% decrease in bioavailability and absorption<br>with food2<br>Long-term safety is not established<br>Not available<br>LDL-C Lowering Bempedoic acid: -17-20%<br>Bempedoic acid + ezetimibe: -38% -60%2<br>PCSK9i: proprotein convertase subtilisin/kexin type 9; MACE-4: CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization; MACE-3: CV death, nonfatal myocardial infarction, or<br>nonfatal stroke 1. Nexletol® (bempedoic acid) Tablets [Package Insert]. Ann Arbor, MI: Esperion Therapeutics, Inc.; 2. J Am Coll Cardiol. 2023 Apr 25;81(16):1553-1564.<br>Esperion has not conducted any head-to-head studies comparing its product candidates to any third party drug products or candidates, whether investigated or approved. Information regarding other drug<br>products in this presentation is meant to provide context for illustrative purposes only. Because there are no head-to-head studies, no conclusions should be made based on cross study comparisons.<br>*estimated trial primary completion date |
| --- |
| Important Safety Information |
| --- |
| NEXLETOL® (bempedoic acid) Important<br>Safety Information<br>25 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br> • NEXLIZET is indicated:<br> • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy<br>(including those not taking a statin) with:<br> • established cardiovascular disease (CVD), or<br> • at high risk for a CVD event but without established CVD.<br> • As an adjunct to diet:<br> • NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.<br> • NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.<br> • NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred.<br> • Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation<br>of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.<br> • Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or<br>fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a<br>history of tendon disorders or tendon rupture.<br> • The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain,<br>abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.<br> • The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver<br>enzymes, muscle spasms, gout, and cholelithiasis.<br> • Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant,<br>breastfeeding is not recommended during treatment with NEXLETOL.<br> • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.<br>See full prescribing information here. |
| --- |
| NEXLIZET® (bempedoic acid and<br>ezetimibe) Important Safety Information<br>26 © 2025 Esperion Therapeutics, Inc. All rights reserved.<br> • NEXLIZET is indicated:<br> • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a<br>statin) with:<br> • established cardiovascular disease (CVD), or<br> • at high risk for a CVD event but without established CVD.<br> • As an adjunct to diet:<br> • NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.<br> • NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.<br> • NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with<br>ezetimibe or bempedoic acid.<br> • Hyperuricemia: Bempedoic acid, a component of NEXLIZET, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following<br>discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.<br> • Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or<br>fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or<br>tendon rupture.<br> • The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid (a component of NEXLIZET) in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia,<br>back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.<br> • Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity,<br>fatigue, and influenza.<br> • In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were<br>urinary tract infection, nasopharyngitis, and constipation.<br> • The most common adverse reactions in the cardiovascular outcomes trial of bempedoic acid (a component of NEXLIZET) at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver<br>enzymes, muscle spasms, gout, and cholelithiasis.<br> • Discontinue NEXLIZET when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended<br>during treatment with NEXLIZET.<br> • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.<br>See full prescribing information here. |
| --- |